Approach to the Advanced Prostate Cancer Clinic for the Urologist

Saturday, September 23, 2023

1:00 PM – 2:00 PM CT

Location: Avenue Ballroom, 4th Floor

CE: 1

Non-Member Speaker(s)

Jason Hafron, MD (he/him/his)

Chief Medical Officer, Director of Clinical Research
Michigan Institute of Urology
Oakland University, William Beaumont School of Medicine

Disclosure(s): Amgen IncMeeting participant/lecturer: Meeting participant/lecturer (Ongoing); Astellas Pharma Inc;: Consultant (Ongoing); Bayer: Meeting participant/lecturer, Scientific Study/Trial (Ongoing); Blue Earth Diagnostics: Consultant (Ongoing); Dendreon Pharmaceuticals LLC: Consultant (Ongoing), Meeting participant/lecturer Scientific Study/Trial (Ongoing); Eli Lilly and Company: Consultant (Ongoing); Immunis.AI: Consultant (Ongoing), Scientific Study/Trial (Ongoing); Janssen Biotech Inc: Consultant (Ongoing), Meeting participant/lecturer, Scientific Study/Trial (Ongoing); Lantheus: Meeting participant/lecturer (Ongoing); Lipella Pharmaceuticals LLC: Scientific Study/Trial (Ongoing); Lynx DX: Consultant (Ongoing); Merck & Co. Inc: Meeting participant/lecturer, Scientific Study/Trial (Ongoing); miR Scientific Inc: Scientific Study/Trial (Ongoing); Myovant Sciences Inc: Consultant (Ongoing), Meeting participant/lecturer, Scientific Study/Trial (Ongoing); Myriad Genetics Inc;: , Meeting participant/lecturer, Scientific Study/Trial (Ongoing), Consultant (Ongoing); Nucleix: Scientific Study/Trial (Ongoing); Pfizer Inc: Consultant (Ongoing), Meeting participant/lecturer, Scientific Study/Trial (Ongoing); Procept-Biorobotic: Meeting participant/lecturer (Ongoing); Promaxo: Consultant (Ongoing); Tolmar Pharmaceuticals Inc: Consultant (Ongoing), Meeting participant/lecturer (Ongoing); Urogen Pharma Inc: Consultant (Ongoing), Meeting participant/lecturer (Ongoing)

Slides

Disclosure(s):

Jason Hafron, MD: Amgen IncMeeting participant/lecturer: Meeting participant/lecturer (Ongoing); Astellas Pharma Inc;: Consultant (Ongoing); Bayer: Meeting participant/lecturer, Scientific Study/Trial (Ongoing); Blue Earth Diagnostics: Consultant (Ongoing); Dendreon Pharmaceuticals LLC: Consultant (Ongoing), Meeting participant/lecturer Scientific Study/Trial (Ongoing); Eli Lilly and Company: Consultant (Ongoing); Immunis.AI: Consultant (Ongoing), Scientific Study/Trial (Ongoing); Janssen Biotech Inc: Consultant (Ongoing), Meeting participant/lecturer, Scientific Study/Trial (Ongoing); Lantheus: Meeting participant/lecturer (Ongoing); Lipella Pharmaceuticals LLC: Scientific Study/Trial (Ongoing); Lynx DX: Consultant (Ongoing); Merck & Co. Inc: Meeting participant/lecturer, Scientific Study/Trial (Ongoing); miR Scientific Inc: Scientific Study/Trial (Ongoing); Myovant Sciences Inc: Consultant (Ongoing), Meeting participant/lecturer, Scientific Study/Trial (Ongoing); Myriad Genetics Inc;: , Meeting participant/lecturer, Scientific Study/Trial (Ongoing), Consultant (Ongoing); Nucleix: Scientific Study/Trial (Ongoing); Pfizer Inc: Consultant (Ongoing), Meeting participant/lecturer, Scientific Study/Trial (Ongoing); Procept-Biorobotic: Meeting participant/lecturer (Ongoing); Promaxo: Consultant (Ongoing); Tolmar Pharmaceuticals Inc: Consultant (Ongoing), Meeting participant/lecturer (Ongoing); Urogen Pharma Inc: Consultant (Ongoing), Meeting participant/lecturer (Ongoing)

Learning Objectives:

Understand the current literature to support the management of patients with metastatic castrate sensitive prostate cancer (mCSPC)
Review the literature for Primary Directed Therapy in Low-Volume mCSPC
Understand the concepts and initial data using metastasis-directed therapy (MDT) of regional and distant recurrences
Review the current management mCRPC
Understand the value of PSMA PET
Understand the basics of implementing an advanced prostate cancer clinic